ReviewHuman vaccines & immunotherapeutics2019
Oral cholera vaccines and their impact on the global burden of disease.
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model.PLoS neglected tropical diseases · 2021Trial
- Attenuating ETEC virulence using a heat-labile enterotoxin-blocking binding protein.Gut microbes · 2026Article
- EPICERTIN, an engineered variant of cholera toxin B subunit, promotes survival and a pro-remodeling macrophage phenotype for mucosal healing in colitis.Mucosal immunology · 2026Article
- Effectiveness of a reactive oral cholera vaccination during a cholera outbreak at the Douala New-Bell Central Prison in Cameroon.PLoS neglected tropical diseases · 2025Article
- Investigation of a suspected cholera outbreak within a closed community of trainees at a college in Hammanskraal, Gauteng Province, South Africa, June 2023.BMC infectious diseases · 2025Article
- Cholera Sicca: A Rare and Atypical Presentation of Vibrio cholerae Infection Mimicking Bowel Obstruction.Cureus · 2025Article
- Dynamics of IgM and IgA Antibody Response Profile AgainstInternational journal of molecular sciences · 2025Article
- Geographic disparities impacting oral vaccine performance: Observations and future directions.Clinical and experimental immunology · 2025Review
- Cost of Cholera for Households and Health Facilities, Somalia.Journal of epidemiology and global health · 2024Article
- Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Review
- The reactive cholera vaccination campaign in urban Dhaka in 2022: experience, lessons learned and future directions.Public health in practice (Oxford, England) · 2024Review
- Cholera resurgence in Africa: assessing progress, challenges, and public health response towards the 2030 global elimination target.Le infezioni in medicina · 2024Review
- Better Existing Water, Sanitation, and Hygiene Can Reduce the Risk of Cholera in an Endemic Setting: Results From a Prospective Cohort Study From Kolkata, India.Open forum infectious diseases · 2023Article
- Review
- Mitigating the effects of climate change on human health with vaccines and vaccinations.Frontiers in public health · 2023Review
- Cholera Infection Risks and Cholera Vaccine Safety in Pregnancy.Infectious diseases in obstetrics and gynecology · 2023Review
- B-Cell Epitope Mapping of theInternational journal of molecular sciences · 2022Article
- Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh.Vaccine: X · 2022Article
- Article
- Conditions to eliminate cholera in Mozambique - the pathway for the development of the national cholera plan.The Pan African medical journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With one-third of nations at risk of cholera, we can expect to experience massive, rapidly disseminated, and prolonged cholera outbreaks such as those recently experienced in Yemen and Haiti. The prevention of cholera outbreaks like these includes the provision of potable water, sanitation, and hygiene (WASH). This approach has been known for generations. However, it will be many years before universal global access to WASH is achieved. While working toward universal WASH, study data has shown that licensed and WHO prequalified cholera vaccines are important tools for cholera prevention. Oral inactivated whole-cell vaccines such as Shanchol and Euvichol-plus provide well-documented direct benefits to vaccine recipients and to the unimmunized through herd protection. Manufacturers have now increased the cholera vaccine supply, and since 2013 vaccine doses have been available for emergency and endemic control through a global stockpile. Advances in packaging and vaccine temperature control, reduced vaccine costs, the inclusion of pregnant women in vaccine campaigns, and a targeted approach to high incidence endemic areas are further increasing the usefulness of these vaccines for reducing the global cholera burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.